Reevaluating HER2-null breast cancer using an enhanced HER2 immunohistochemistry protocol

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background : Human epidermal growth factor receptor 2 (HER2) status is crucial for the classification of breast cancer and selection of its treatment. Although HER2-low breast cancer is a recognized therapeutic subgroup, the classification of HER2 immunohistochemistry (IHC) 0 remains unclear. Methods : We reassessed 58 HER2-null breast cancer cases using an enhanced HER2 IHC protocol and the VENTANA OptiView detection system. HER2 expression was evaluated based on membrane positivity rate (%) and staining intensity. Microscopic assessment was performed to determine the percentage of HER2-positive tumor cells. Digital image analysis was used to quantify staining intensity. Results : Membrane HER2 positivity was detected to varying degrees in all cases. This indicated that tumors previously classified as HER2-null exhibited HER2 expression when analyzed with the enhanced detection system. Conclusion : These findings suggest that enhanced HER2 IHC protocols can improve detection sensitivity. Further research is needed to determine the clinical significance of HER2 expression detected using enhanced protocols.

Article activity feed